Vesicular stomatitis virus (VSV) matrix protein (MP) can induce in vitro apoptosis of tumor cells in the absence of other viral components. Here, the antitumor activity of VSV-MP against lung adenocarcinoma was investigated in vivo. A pVAX-plasmid DNA encoding VSV-MP and control empty vectors (pVAX) were constructed and wrapped-up with liposome. A549 and Spc-A1 human lung adenocarcinoma cells were transfected with liposomal-VSV-MP (Lip-MP) or Lip-pVAX and then examined for cell viability or apoptosis using Hoechst/propidium iodide staining by flow cytometry, and further demonstrated by caspase/poly ADP-ribose polymerase (PARP) cleavage analysis. For the in vivo study, A549 and Spc-A1 lung carcinoma models in nude mice were established and randomly assigned into three groups to receive eight 2-weekly intravenous administrations of medium alone as control, Lip-pVAX or Lip-MP, respectively. Subsequently, Lip-MP significantly reduced tumor growth and prolonged the survival of tumor-bearing mice compared with Lip-pVAX and control agents (Po0.05), with much higher apoptosis index of both in vivo and in vitro tumor cells, respectively (Po0.05). In addition, in vivo antitumoral effect was associated with natural killer-(NK) cell congregation without evidence of toxicity. These observations suggest that systemically delivering Lip-MP has a specific dual antitumor activity in human lung adenocarcinoma by inducing apoptosis and possibly stimulating NK-cell responses, it may provide a clue for developing new therapeutic approaches against human lung adenocarcinoma.
Introduction
Lung cancer, one of the most prevalent neoplasias in developed countries and the leading cause of cancer death in the world today, is poised to claim approximately one billion lives during the 21st century. [1] [2] [3] Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, accounts for approximately 85% of all cases of lung cancer wherein adenocarcinoma has become the commonest subtypes of NSCLC in the recent decades. Aggressive surgical debulking operation along with multimodal chemotherapy has therapeutically benefited patients with NSCLC and newly developed biotherapies along with radiation therapy may be helpful supplements. Despite this, a survival plateau has been reached. In view of the limited success of current treatment modalities for NSCLC, more effective strategies need to be developed. 4 Vesicular stomatitis virus (VSV), a negative-stranded RNA rhabdovirus with a genome of single molecule that contains five major proteins (nucleoprotein N, phosphoprotein P, matrixprotein M, glycoprotein G and polymerase L), can preferentially replicate in immortalized and malignant cells and finally induce apoptosis. 5, 6 Studies by a number of researchers have also confirmed that VSV can suppress the growth of various tumors in vivo and prolong the survival time of tumor-bearing mice when introduced intratumorally or intravenously in tumor-bearing animal models. [6] [7] [8] [9] [10] [11] [12] [13] However, the application of VSV is limited by the potential biohazard such as flu-like symptoms and, less commonly, oral vesicles or cervical lymphadenopathy. 14 Recent studies have shown that the vesicular stomatitis virus matrix protein (VSV-MP), a structural component of the virion, can cause considerable cytopathogenesis of VSV in the absence of other viral components. The mechanisms are the general inhibition of host gene expression at the level of transcription, 6, [15] [16] [17] [18] [19] [20] [21] [22] repression of nucleocytoplasmic transport of host RNAs and proteins, [23] [24] [25] including the disruption of all three types of cytoskeletal elements. 26, 27 Considering that gene transfer of VSV-MP was able to induce apoptosis in vitro and inhibit the growth of a few tumors in vivo, [28] [29] [30] it was designed to investigate whether the VSV-MP recombinant could potentiate the antitumor activity for advanced lung adenocarcinoma in vitro and in vivo in the present study.
Materials and methods

Cell culture conditions
Human lung adenocarcinoma cell lines A549 and Spc-A1 were obtained from American Type Culture Collection (Rockville, MD) and cultured in RPMI 1640 medium (Life Technologies, Bedford, MA) supplemented with 10% heat-inactivated fetal bovine serum, 100 mg ml À1 amikacin. Cells were maintained in a humid 5%-CO 2 incubator at 37 1C and passaged every 3 days at a split ratio of 1:4 using trypsin.
Plasmid construction and liposome preparation pVAX plasmid (Invitrogen, San Diego, CA) encoded wild-type VSV-MP, was constructed in our laboratory as reported previously by us. 30 As a control, pVAX plasmid without VSVMP-cDNA was prepared the same way as an empty vector.
DOTAP:Chol cationic liposomes were prepared using the procedure described previously. Briefly, lipids DOTAP (dioleyl trimethylammonium propane; Avanti Polar Lipids Inc., AL) and DOPE (dioleyl phosphatidylethanolamine; Avanti Polar Lipids Inc.,) (1:1 molar ratio) were dissolved in chloroform supplemented with methanol (3:1 volume ratio). The resulting mixture was dried in a rotary 100-ml round-bottomed flask and organic solvent was further removed under vacuum for 2 h. The lipid film was hydrated in an appropriate amount of sterile water to yield a final concentration of 5 mg ml
À1
. Then the liposome solution was vortexed for 1 min, sonicated for 10 min to form small unilamellar vesicles and stored at 4 1C.
Preparations of plasmid:liposome complexes pVAX plasmid DNA:liposome complexes were prepared half an hour before tail vein injection or in vitro experiment. Briefly, DNA and stock liposomes were diluted in D5W (dextrose 5% in water) or 1640 medium without serum and mixed in equivolume solutions, with a DNA/liposome ratio of 1:4 (mg/mg). Dilution and mixing were performed in 1.5-ml Eppendorf tubes with all reagents at room temperature. The DNA solution was added rapidly at the surface of the liposome solution using a Pipetman tip (Ai Bend AG, Hamburg, Germany), mixed gently by pipetting up and down, and then incubated at room temperature for 30 min before use.
Morphological analysis A549/Spc-A1 cells (1 Â 10 5 ) were grown in each well of 6-well plates and incubated for 24 h to 50% confluence. Cells received the corresponding treatment; (a) Control: medium alone, (b) Lip-pVAX: 2 mg pVAX/8 mg liposome complexes and (c) Lip-MP: 2 mg pVAX-MP/8 mg liposome complexes. The cells were incubated with the above agents for 6 h, the medium was then changed by adding 2 ml of RPMI 1640 supplemented with fetal calf serum and incubated for additional 48 h. Then, cells were examined for morphological changes by inverted phase contrast microscope. Briefly, after being processed in 6-well plates as described above, the A549/Spc-A1 cells were collected and rinsed with phosphate-buffered saline (PBS), and thereafter stained for 30 min with 50 mg PI per ml in 0.1% sodium citrate plus 0.1% Triton X-100, examined by fluorescence microscope (Zeiss, Axiovert 200, Oberkochen, Germany) finally.
Apoptosis assay
In addition, quantitative evaluation of cellular apoptosis was performed by flow cytometric analysis using propidium iodide (PI) staining method. After the same procession of A549/Spc-A1 cells in 6-well plates as described above, the floated cells were discarded and the attached cells were trypsinized, and thereafter washed twice with cold PBS. Cells were resuspended in prediluted binding buffer and stained with hypotonic PI solution containing 50 mg PI per ml in 0.1% sodium citrate plus 0.1% Triton X-100 and examined with flow cytometry and fluorescence microscopy. Apoptosis was also observed by Hoechst 33258 staining. Briefly, cells were immersed in 0.5 ml of methanol for 10 min, followed by rinsing with PBS twice. Then cells were stained with 1 mg ml À1 Hoechst 33258 compounds in a dark chamber at room temperature for 10 min and rinsed twice in PBS again. Cells were analyzed by fluorescence microscopy using excitation 348 nm/emission 480 nm wavelengths. The apoptotic cells are featured as pyknotic and fragmented nuclei emitting intense fluorescence.
Western blotting
For the identification of pathway by which the VSV-MP induces apoptosis, Tumor cells treated with Lip-pVAX, Lip-MP or medium alone as control were washed in cold PBS twice and harvested in RIPA lysis buffer. Cellular protein was quantitated by Bradford assay (Bio-Rad, Hercules, CA, USA), and 50 mg of the cleared lysates were separated on a 12% SDS-PAGE, and electro-transferred onto PVDF membranes (Amersham Pharmacia Biotech, Little Chalfont, UK), then were blocked in Tris-buffered saline containing 0.1% Tween 20 with 5% nonfat dry milk for 2 h and incubated with rabbit mAb against cleaved-PARP (Asp214, Cell Signaling Technology, Boston, MA, USA) over night. Then the membranes were washed for 5 min in phosphate buffered saline tween-20 (PBST) thrice, followed by incubation with goat antirabbit secondary antibody at 1:5000 dilution (Abcam, Cambridge, UK) in PBST for 1 h. After three times of washing with PBST and two times with PBS for 5 min, the bands were developed using the enhanced chemiluminescence detection system (Pierce Biotech Inc., Rockford, IL).
In vivo animal treatment protocol Female athymic BALB/c nude mice (SPF grade), 6-8-weeks old, were housed in autoclaved microisolator cages in an air-filtered laminar flow cabinet, and were given food and water ad libitum. All procedures were performed under sterile conditions in a laminar flow hood and all studies involving mice were approved by the institute's animal care and use committee.
A549 and Spc-A1(6 Â 10 5 cells in 100 ml of RPMI 1640 medium) adenocarcinoma cells were injected into the right flank of BALB/c nude mice via subcutaneous inoculation. When tumors were palpable after inoculation, mice were randomly assigned into one of the following three groups: (a) Control: mice treated with 200 ml of 5% glucose solution, (b) Lip-pVAX: mice treated with 25 mg pVAX/ 100 mg liposome complexes and (c) Lip-MP: mice treated with 25 mg pVAX-MP/100 mg liposome complexes. They received eight 2-weekly intravenous administrations and were monitored every 3 days for tumor burden, cachexia and other abnormalities. Tumor sizes were measured using the formula A Â B 2 Â 0.52 (A, length; B, width; all measured in millimeters). The survival time of those mice treated with the protocols described above was observed (five mice in each group). Mice were killed when the volume of tumor exceeded 5000 mm 3 , and the day of killing of the mouse was considered as its survival time.
Histologic analysis
The tumors and organs, including heart, lung, liver, kidney, brain and spleen, were harvested, fixed in the 4% paraformaldehyde in PBS, embedded in paraffin and cut into 3-5 mm sections. Then the sections were stained with hematoxylin and eosin. Apoptosis of tumor tissues was detected by TUNEL (Promega, Madison, WI) and immunohistochemical staining for natural killer (NK) cell was performed with anti-NK-1 monoclonal antibody (1:800; BD Pharmingen, San Diego, CA, USA), following the manufacturer's protocol. Images of tumor tissue were taken by using Olympus BX600 microscope (Olympus, Tokyo, Japan).
Statistical analysis
Statistical analysis of comparisons of tumor volume and percent apoptosis were performed using one-way analysis of variance. Survival curves were based on the KaplanMeier method and statistical significance was determined by the log-rank test; Po0.05 was defined as significant.
Results
Lip-MP induced tumor-cell growth arrest in vitro A549/Spc-A1 cells were seeded in 6-well plates and incubated with medium alone as control, Lip-pVAX or Lip-MP, respectively. As shown in Figure 1a , Lip-MP resulted in obvious morphological changes consistent with apoptosis in contrast to Lip-pVAX and control agents, which were characterized by cell rounding, membrane blebbing, cytoplasmic condensation and detachment from the culture dish after 48 h treatment. The morphological changes of A549/Spc-A1 cells were also characteristic of apoptosis after PI staining; brightly red, fluorescent condensed nuclei (intact or fragmented) and apoptotic bodies in contrast to control agents. Apoptosis index was also conducted on A549/Spc-A1 cells. After 48 h of treatment, Lip-MP administration resulted in increased number of apoptotic cells and decreased cell viability compared with the control agents (Supplementary Figure 1 ). It seems likely that the inhibition of cell proliferation by Lip-MP may in part be a result of apoptotic cell death and viability suppression (Figure 1b) .
Lip-MP induced apoptosis evaluated by flow cytometry and western blotting Flow cytometry was used to evaluate whether the cell growth inhibition of Lip-MP was associated with apoptosis induction. From the results of flow cytometry, we found that the apoptotic cells accounted for 60.4% in Lip-MP group versus 32.7% in Lip-pVAX group and 28.8% in medium-alone group in A549 tumor model; in Spc-A1 tumor model, the apoptotic cells accounted for 57.2% in Lip-MP group versus 19.8% in Lip-pVAX group and 11.8% in medium-alone group (Figure 2) . Lip-MP prolonged the survival time of both A549 and Spc-A1 models Survival of the tumor-bearing mice treated with Lip-MP in the two tumor models was significantly prolonged compared with the control agents (Po0.05). As shown in the Kaplan-Meier survival curve displayed in Figure 4 , the Lip-MP-treated group in both A549 and Spc-A1 tumor models lived dramatically longer than the LippVAX-treated mice and the control alone with a median survival of 141 and 151 days in contrast to 92 and 88 days, and 85 and 74 days, respectively. Ultimately, more than 40% of hosts in Lip-MP group have survived over the 150-day-long study period versus 0 in Lip-pVAX and control groups in both A549 and Spc-A1 tumor models (Po0.05, by log-rank test). No statistically significant difference in survival among Lip-pVAX and control groups was found in the two tumor models (P40.05).
Lip-MP increased intratumoral apoptosis of both A549
and Spc-A1 models Decreased tumor burden was associated with an increased rate of tumor cell apoptosis. Immunofluorescence microscopy of TUNEL staining showed many positive nuclei in Lip-MP-treated tumor tissues, whereas such nuclei were rare in tumor tissues of control groups (Figure 5a ). In both A549 and Spc-A1 models, quantification of apoptotic cells within tumor sections revealed that Lip-MP induced a significant enhancement of apoptosis cells, with the apoptosis index of 3.75±0.9186%/5.4±1.0398% compared with 0.75 ± 0.1768%/1.9 ± 0.6519% (LippVAX), 0.35±0.1369%/0.5±0.25% (control alone), respectively (Po0.05, Figure 5b ).
Lip-MP activated NK accumulation in both A549 and Spc-A1 models Administration of Lip-MP resulted in abundant lymphocyte accumulation in both A549 and Spc-A1 models. Tumor tissues from Lip-MP groups were detected toward poorly proliferating, with numerous lymphocytes congregating around or infiltrating into the remnant tumor cells. In contrast, tumor cell nests in Lip-pVAX and control groups have kept active proliferation. Anti-NK1 antibody staining showed that there were very few or almost no NK-1 þ lymphocytes (activated NK) infiltrating the tumor cell nests of Lip-pVAX and control groups; whereas lymphocyte accumulation in Lip-MP groups almost consisted of activated NK cells. Both A549
and Spc-A1 models showed similar staining responses ( Figure 6 ).
Toxicity observation
No gross abnormalities were found in the Lip-MP-treated mice. Furthermore, no significant differences in liver, lung, kidney, spleen, heart, pancreas and brain were observed by hematoxylin and eosin histological examination under microscope between Lip-MP group and the control mice.
Discussion
Human lung adenocarcinoma, the most prevalent subtype of NSCLC, presents a continuing therapeutic challenge as the therapeutic effects of the modalities available now are still limited. Therefore, it is sensible to exploit an innovative and safe therapeutic strategy aimed at the development of lung adenocarcinoma.
In the study, we have demonstrated the significant suppression of Lip-MP on subcutaneous xenograft growth of human lung adenocarcinoma cancer, and its prolongation of survival time in both A549 and Spc-A1 animal models. This study provides proof of the principle that VSV-MP possesses antitumor activity against human lung cancer in vivo in the absence of other viral components by induction of apoptosis and activity of NK cells, opening ways for future investigations of this approach. VSV, as well as other viruses including measles virus, adenovirus, retrovirus, reovirus, poxvirus, influenza virus, herpes simplex virus and Newcastle disease virus, have been actively developed as oncolytic agents for cancer treatment. 31 The reason why we choose VSV-MP, a single viral component, as an antitumor approach instead of VSV itself is the potential biohazard of VSV application. Infection of humans with VSV can cause flu-like symptoms and, less commonly, oral vesicles or cervical lymphadenopathy, which indicates the application of VSV in human beings should be limited because of its potential adverse effects. Therefore, we used VSV-MP as an antitumor agent for human lung adenocarcinoma cancer models. The gene transfers of VSV-MP in the animal models were the first utilization of MP as an antitumor approach to human lung cancer.
In vitro, we had made several observations concerning the antitumor mechanism of VSV-MP on A549 and Spc-A1 lung cancer cells, including morphological analysis, PI staining, fluorescence microscopy and flow cytometric analysis of apoptotic cells. Our findings demonstrated that the VSV-MP had potent activity against human lung cancer cells in vitro by triggering apoptosis of cancer cells. Lip-MP Lip-pVAX Figure 6 Histological analysis of tumors among different groups. Sections of paraffin-embedded tissues from the two models were stained with hematoxylin and eosin and anti-NK1 antibody. For hematoxylin and eosin staining, tumor tissues from Lip-MP group were detected toward poorly proliferating, with numerous lymphocytes congregating around or infiltrating into the remnant tumor cells. In contrast, tumor tissues or nests in Lip-pVAX and control groups have kept active proliferation surrounding adenocarcinoma-associated mucinous lakes (top and middle-upper panels). As for anti-NK1 antibody staining, there were only few or almost no NK-1 þ lymphocytes (activated NK) infiltrating the tumor cell nests (arrow) of Lip-pVAX and control groups; whereas lymphocyte accumulation in Lip-MP group almost consisted of activated NK cells (middle-lower and bottom panels). Both A549 and Spc-A1 models demonstrated similar staining responses (Po0.05 for pVAX-MP versus Lip-pVAX and control).
In the present study, VSV-MP exhibited potent antitumor effects against human lung adenocarcinoma cancer A549 and Spc-A1 models, without obvious systemic toxicity, and thus significantly prolonged the survival period of treated mice. Compared with the controls, VSV-MP resulted in visible inhibition of tumor volume with few or no skin ulceration during the therapy course, which might be related to the retardation of tumor progression by VSV-MP treatment. To elucidate the possible antitumor mechanism of VSV-MP in vivo, TUNEL assay was conducted in tumor tissue, which exhibited that VSV-MP resulted in abundant apoptosis of tumor cells compared with controls. The result is consistent with the mechanism of VSV-MP-induced cytopathogenesis demonstrated in vitro previously. Recent researches regarding VSV-MP were predominantly focusing on its capacity to inhibit the growth of a few tumors in vivo. [28] [29] [30] It is possible that the antitumor efficacy of VSV-MP in vivo is mainly through directly inhibiting the growth of tumor cells by apoptosis induction of tumor cells; the mechanisms by which the VSV-MP induces apoptosis are disorganization of cytoskeletal elements 26, 27 and general inhibition of host cell gene expression, 6, 15, 16 the downregulation of MMP-9 in VSV-MP-treated group may contribute to the therapeutic effect. Besides, it is unclear whether angiogenesis that can be inhibited by endothelial cell apoptosis has a vital role in tumor growth and metastasis, the researches reported are controversial. 29, 30 Moreover, human antitumor effector cells include class I major histocompatibility complex-restricted T cells and non-major histocompatibility complex-restricted NK cells; when seen from the immunohistochemical staining, Lip-MP seemed to have the ability to activate NK cells. The implications of this interaction between NK cells and the antitumoral effects of Lip-MP should be discussed. It may be hypothesized that the VSV-MP may be a novel NK cell-derived factor involved to elevate the level of NK cells, which have been demonstrated to mediate potent antitumor activities.
In summary, the combination of pVAX plasmid with VSV-MP reduced tumor burden and achieved survival improvement in both A549 and Spc-A1 animal models. Given the strong antitumor effect and minimal toxicity, the results of our study may be of importance to the further exploration of potential application of the combined approach in the treatment of human lung adenocarcinoma.
